

Scott D Grosse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7697530/publications.pdf>

Version: 2024-02-01

248
papers

13,489
citations

20817

60
h-index

28297

105
g-index

257
all docs

257
docs citations

257
times ranked

15023
citing authors

#	ARTICLE	IF	CITATIONS
1	New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. <i>Reviews in Medical Virology</i> , 2007, 17, 355-363.	8.3	969
2	Assessing cost-effectiveness in healthcare: history of the \$50,000 per QALY threshold. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 165-178.	1.4	543
3	Sickle Cell Disease in Africa. <i>American Journal of Preventive Medicine</i> , 2011, 41, S398-S405.	3.0	470
4	The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. <i>Thrombosis Research</i> , 2016, 137, 3-10.	1.7	345
5	Strategies for Implementing Screening for Critical Congenital Heart Disease. <i>Pediatrics</i> , 2011, 128, e1259-e1267.	2.1	344
6	Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States. <i>Health Services Research</i> , 2018, 53, 175-196.	2.0	330
7	Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: A quantitative assessment. <i>Journal of Clinical Virology</i> , 2008, 41, 57-62.	3.1	301
8	Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease: A Scientific Statement from the AHA and AAP. <i>Pediatrics</i> , 2009, 124, 823-836.	2.1	275
9	Economic gains resulting from the reduction in children's exposure to lead in the United States.. <i>Environmental Health Perspectives</i> , 2002, 110, 563-569.	6.0	266
10	The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. <i>Genetics in Medicine</i> , 2010, 12, 93-104.	2.4	250
11	What is the clinical utility of genetic testing?. <i>Genetics in Medicine</i> , 2006, 8, 448-450.	2.4	244
12	Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease. <i>Circulation</i> , 2009, 120, 447-458.	1.6	220
13	Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. <i>International Journal of Infectious Diseases</i> , 2014, 22, 44-48.	3.3	176
14	Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level?. <i>Archives of Disease in Childhood</i> , 2011, 96, 374-379.	1.9	169
15	Attention-Deficit/Hyperactivity Disorder Symptoms and Child Maltreatment: A Population-Based Study. <i>Journal of Pediatrics</i> , 2008, 153, 851-856.	1.8	166
16	Emergency Department Visits Made by Patients with Sickle Cell Disease. <i>American Journal of Preventive Medicine</i> , 2010, 38, S536-S541.	3.0	166
17	Models of Comprehensive Multidisciplinary Care for Individuals in the United States With Genetic Disorders. <i>Pediatrics</i> , 2009, 123, 407-412.	2.1	147
18	Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2007, 79, 552-558.	1.6	145

#	ARTICLE	IF	CITATIONS
19	Trends in Pediatric Sickle Cell Disease-Related Mortality in the United States, 1983-2002. <i>Journal of Pediatrics</i> , 2009, 154, 541-545.	1.8	133
20	Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection. <i>Pediatrics</i> , 2017, 139, .	2.1	129
21	Medical Expenditures for Children with an Autism Spectrum Disorder in a Privately Insured Population. <i>Journal of Autism and Developmental Disorders</i> , 2008, 38, 546-552.	2.7	128
22	The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. <i>Genetics in Medicine</i> , 2006, 8, 205-212.	2.4	125
23	Children with Orofacial Clefts: Health-Care Use and Costs among a Privately Insured Population. <i>Public Health Reports</i> , 2009, 124, 447-453.	2.5	124
24	Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 765-778.	2.1	120
25	Autism Spectrum Disorders and Health Care Expenditures. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2012, 33, 2-8.	1.1	116
26	Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics. <i>Public Health Genomics</i> , 2010, 13, 106-115.	1.0	114
27	From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels. <i>Pediatrics</i> , 2006, 117, 923-929.	2.1	112
28	Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. <i>Genetics in Medicine</i> , 2008, 10, 648-654.	2.4	112
29	Economic Productivity by Age and Sex. <i>Medical Care</i> , 2009, 47, S94-S103.	2.4	108
30	Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2111.	7.4	106
31	Lessons from Cost-Effectiveness Research for United States Public Health Policy. <i>Annual Review of Public Health</i> , 2007, 28, 365-391.	17.4	105
32	Challenges of translating genetic tests into clinical and public health practice. <i>Nature Reviews Genetics</i> , 2009, 10, 489-495.	16.3	101
33	Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. <i>Medical Decision Making</i> , 2010, 30, 328-340.	2.4	99
34	Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 74.e1-74.e9.	1.3	99
35	Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. <i>Journal of Pediatrics</i> , 2006, 149, 362-366.	1.8	98
36	Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. <i>Pediatric Blood and Cancer</i> , 2009, 53, 642-646.	1.5	96

#	ARTICLE	IF	CITATIONS
37	Inpatient Hospitalization Costs Associated with Birth Defects Among Persons of All Ages â€” United States, 2013. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 41-46.	15.1	95
38	Retrospective Assessment of Cost Savings From Prevention. <i>American Journal of Preventive Medicine</i> , 2016, 50, S74-S80.	3.0	94
39	Reevaluating the Benefits of Folic Acid Fortification in the United States: Economic Analysis, Regulation, and Public Health. <i>American Journal of Public Health</i> , 2005, 95, 1917-1922.	2.7	91
40	Cost-Effectiveness of Routine Screening for Critical Congenital Heart Disease in US Newborns. <i>Pediatrics</i> , 2013, 132, e595-e603.	2.1	91
41	Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. <i>Thrombosis Research</i> , 2015, 135, 50-57.	1.7	91
42	Issues related to the diagnosis and treatment of autism spectrum disorders. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2007, 13, 129-135.	3.6	87
43	The Impact of Transient Hypothyroidism on the Increasing Rate of Congenital Hypothyroidism in the United States. <i>Pediatrics</i> , 2010, 125, S54-S63.	2.1	85
44	Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children. <i>Research in Developmental Disabilities</i> , 2012, 33, 832-840.	2.2	83
45	Are lower TSH cutoffs in neonatal screening for congenital hypothyroidism warranted?. <i>European Journal of Endocrinology</i> , 2017, 177, D1-D12.	3.7	81
46	Second-hand Smoke Exposure and Blood Lead Levels in U.S. Children. <i>Epidemiology</i> , 2003, 14, 719-727.	2.7	80
47	Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia. <i>Pediatrics</i> , 2013, 132, 677-683.	2.1	77
48	Sickle Cell Diseaseâ€™s Related Pediatric Medical Expenditures in the U.S.. <i>American Journal of Preventive Medicine</i> , 2010, 38, S550-S556.	3.0	74
49	Personal utility and genomic information: Look before you leap. <i>Genetics in Medicine</i> , 2009, 11, 575-576.	2.4	73
50	Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. <i>Genetics in Medicine</i> , 2017, 19, 121-126.	2.4	73
51	Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. <i>MMWR Recommendations and Reports</i> , 2004, 53, 1-36.	61.1	73
52	Health Care Expenditures for Infants and Young Children with Down Syndrome in a Privately Insured Population. <i>Journal of Pediatrics</i> , 2008, 153, 241-246.	1.8	71
53	Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2â€™5 Years â€™ United States, 2008â€™2014. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 443-450.	15.1	71
54	Healthcare expenditures for males with haemophilia and employerâ€™sponsored insurance in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 268-275.	2.1	69

#	ARTICLE	IF	CITATIONS
55	Professional Fee Ratios for US Hospital Discharge Data. <i>Medical Care</i> , 2015, 53, 840-849.	2.4	68
56	Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. <i>BMC Pediatrics</i> , 2010, 10, 9.	1.7	67
57	Prevalence of Congenital Hypothyroidism—Current Trends and Future Directions: Workshop Summary. <i>Pediatrics</i> , 2010, 125, S31-S36.	2.1	67
58	Disability and Disability-Adjusted Life Years: Not the Same. <i>Public Health Reports</i> , 2009, 124, 197-202.	2.5	66
59	Hospitalizations, costs, and mortality among infants with critical congenital heart disease: How important is timely detection?. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2013, 97, 664-672.	1.6	66
60	How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?. <i>Hormone Research in Paediatrics</i> , 2007, 67, 284-291.	1.8	63
61	Healthcare expenditures for privately insured people with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2009, 44, 989-996.	2.0	63
62	Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. <i>Haemophilia</i> , 2012, 18, 276-283.	2.1	63
63	Trends in Venous Thromboembolism-Related Hospitalizations, 1994–2009. <i>Pediatrics</i> , 2012, 130, e812-e820.	2.1	61
64	U.S. Trends in Computed Tomography Use and Diagnoses in Emergency Department Visits by Patients With Symptoms Suggestive of Pulmonary Embolism, 2001–2009. <i>Academic Emergency Medicine</i> , 2013, 20, 1033-1040.	1.8	59
65	Attention-Deficit/Hyperactivity Disorder, Conduct Disorder, and Young Adult Intimate Partner Violence. <i>Archives of General Psychiatry</i> , 2010, 67, 1179.	12.3	58
66	Health state preference scores of children with spina bifida and their caregivers. <i>Quality of Life Research</i> , 2005, 14, 1087-1098.	3.1	57
67	Cost-effectiveness of a folic acid fortification program in Chile. <i>Health Policy</i> , 2007, 83, 295-303.	3.0	57
68	The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. <i>Genetics in Medicine</i> , 2014, 16, 33-39.	2.4	56
69	A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability. <i>Research in Developmental Disabilities</i> , 2014, 35, 1518-1527.	2.2	56
70	Folic acid supplementation and neural tube defect recurrence prevention. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2007, 79, 737-742.	1.6	55
71	Preterm birth lifetime costs in the United States in 2016: An update. <i>Seminars in Perinatology</i> , 2021, 45, 151390.	2.5	55
72	Economic Evaluation of a Neural Tube Defect Recurrence—Prevention Program. <i>American Journal of Preventive Medicine</i> , 2008, 35, 572-577.	3.0	51

#	ARTICLE	IF	CITATIONS
73	Administrative Data Sets and Health Services Research on Hemoglobinopathies. American Journal of Preventive Medicine, 2010, 38, S557-S567.	3.0	50
74	Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health. American Journal of Preventive Medicine, 2017, 53, S115-S117.	3.0	50
75	Evaluation of the Validity and Utility of Genetic Testing for Rare Diseases. Advances in Experimental Medicine and Biology, 2010, 686, 115-131.	1.6	50
76	The Economic Costs of Autism: A Review. , 2011, , 1347-1360.		50
77	Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genetics in Medicine, 2018, 20, 383-389.	2.4	49
78	Trends in In-Hospital Deaths Among Hospitalizations With Pulmonary Embolism. Archives of Internal Medicine, 2012, 172, 960-1.	3.8	48
79	ECONOMIC COSTS OF MENTAL RETARDATION, CEREBRAL PALSY, HEARING LOSS, AND VISION IMPAIRMENT. Research in Social Science and Disability, 0, , 207-228.	0.1	46
80	Newborn screening for congenital cytomegalovirus: Options for hospital-based and public health programs. Journal of Clinical Virology, 2009, 46, S32-S36.	3.1	46
81	Factors Associated With Late Detection of Critical Congenital Heart Disease in Newborns. Pediatrics, 2013, 132, e604-e611.	2.1	44
82	Health Care Utilization and Expenditures for Children and Young Adults With Muscular Dystrophy in a Privately Insured Population. Journal of Child Neurology, 2008, 23, 883-888.	1.4	43
83	Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recommendations and Reports, 2004, 53, 1-29.	61.1	43
84	Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Tropical Medicine and International Health, 2015, 20, 184-187.	2.3	42
85	Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014. Genetics in Medicine, 2018, 20, 428-434.	2.4	42
86	Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time. Pharmacoeconomics, 2019, 37, 461-473.	3.3	42
87	A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola. Journal of Pediatrics, 2015, 167, 1314-1319.	1.8	41
88	Employer-Sponsored Plan Expenditures for Infants Born Preterm. Pediatrics, 2017, 140, .	2.1	41
89	Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State. Journal of Pediatrics, 2016, 172, 127-135.	1.8	40
90	Employment impact and financial burden for families of children with fragile X syndrome: findings from the National Fragile X Survey. Journal of Intellectual Disability Research, 2010, 54, 918-928.	2.0	38

#	ARTICLE	IF	CITATIONS
91	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 12.	2.7	38
92	Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. <i>Maternal and Child Health Journal</i> , 2016, 20, 693-700.	1.5	38
93	Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book. <i>American Journal of Preventive Medicine</i> , 2018, 54, 600-602.	3.0	38
94	A Public Health Economic Assessment of Hospitals' Cost to Screen Newborns for Critical Congenital Heart Disease. <i>Public Health Reports</i> , 2014, 129, 86-93.	2.5	37
95	Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. <i>Journal of Medical Economics</i> , 2019, 22, 501-508.	2.1	37
96	Infants with Congenital Disorders Identified Through Newborn Screening – United States, 2015–2017. <i>Morbidity and Mortality Weekly Report</i> , 2020, 69, 1265-1268.	15.1	37
97	The Cost Effectiveness of Universal versus Selective Newborn Screening for Sickle Cell Disease in the US and the UK. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 239-247.	2.1	36
98	Spending by California's Department of Developmental Services for Persons with Autism across Demographic and Expenditure Categories. <i>PLoS ONE</i> , 2016, 11, e0151970.	2.5	36
99	Hospital use and associated costs of children aged zero to two years with craniofacial malformations in Massachusetts. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2009, 85, 925-934.	1.6	35
100	Impact of Spina Bifida on Parental Caregivers: Findings from a Survey of Arkansas Families. <i>Journal of Child and Family Studies</i> , 2009, 18, 574-581.	1.3	35
101	Hospitalization for urinary tract infections and the quality of preventive health care received by people with spina bifida. <i>Disability and Health Journal</i> , 2009, 2, 145-152.	2.8	35
102	Utilization of a Medicaid-Funded Intervention for Children With Autism. <i>Psychiatric Services</i> , 2009, 60, 549-552.	2.0	35
103	Disability Among Individuals with Sickle Cell Disease. <i>American Journal of Preventive Medicine</i> , 2011, 41, S390-S397.	3.0	35
104	Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. <i>Genetics in Medicine</i> , 2013, 15, 222-228.	2.4	35
105	Measuring health and well-being effects in family caregivers of children with craniofacial malformations. <i>Quality of Life Research</i> , 2011, 20, 1487-1495.	3.1	34
106	Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. <i>Genetics in Medicine</i> , 2012, 14, 703-712.	2.4	34
107	Cost-effectiveness of Increasing Access to Contraception during the Zika Virus Outbreak, Puerto Rico, 2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 74-82.	4.3	34
108	Does newborn screening save money? The difference between cost-effective and cost-saving interventions. <i>Journal of Pediatrics</i> , 2005, 146, 168-170.	1.8	33

#	ARTICLE	IF	CITATIONS
109	Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010–2016. <i>Pediatric Pulmonology</i> , 2018, 53, 1611-1618.	2.0	33
110	<i>BRCA</i> Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. <i>MMWR Surveillance Summaries</i> , 2017, 66, 1-11.	34.6	33
111	Determining the Effect of Newborn Hearing Screening Legislation: An Analysis of State Hearing Screening Rates. <i>Public Health Reports</i> , 2007, 122, 198-205.	2.5	32
112	Actions in Support of Newborn Screening for Critical Congenital Heart Disease – United States, 2011–2018. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 107-111.	15.1	32
113	Labor Market Productivity Costs for Caregivers of Children with Spina Bifida: A Population-Based Analysis. <i>Medical Decision Making</i> , 2009, 29, 23-32.	2.4	31
114	Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 249-254.	3.6	31
115	QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 293-308.	1.4	31
116	Medical expenditures of children in the United States with fetal alcohol syndrome. <i>Neurotoxicology and Teratology</i> , 2011, 33, 322-324.	2.4	31
117	When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives. <i>Healthcare (Switzerland)</i> , 2015, 3, 860-878.	2.0	31
118	Universal State Newborn Screening Programs Can Reduce Health Disparities. <i>JAMA Pediatrics</i> , 2015, 169, 7.	6.2	30
119	The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. <i>Genetics in Medicine</i> , 2015, 17, 510-511.	2.4	30
120	Quantifying the health benefits of genetic tests: The importance of a population perspective. <i>Genetics in Medicine</i> , 2006, 8, 191-195.	2.4	29
121	Late-Treated Phenylketonuria and Partial Reversibility of Intellectual Impairment. <i>Child Development</i> , 2010, 81, 200-211.	3.0	29
122	Health state preference scores for children with permanent childhood hearing loss: a comparative analysis of the QWB and HUI3. <i>Quality of Life Research</i> , 2008, 17, 943-953.	3.1	27
123	Attitudes Toward Newborn Screening for Cytomegalovirus Infection. <i>Pediatrics</i> , 2011, 128, e1434-e1442.	2.1	27
124	Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1. <i>Genetics in Medicine</i> , 2017, 19, 975-982.	2.4	27
125	Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. <i>Health Affairs</i> , 2018, 37, 773-779.	5.2	27
126	Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. <i>Healthcare (Switzerland)</i> , 2015, 3, 1133-1157.	2.0	26

#	ARTICLE	IF	CITATIONS
127	Mortality of New York children with sickle cell disease identified through newborn screening. <i>Genetics in Medicine</i> , 2015, 17, 452-459.	2.4	26
128	Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005â€“2010. <i>Thrombosis Research</i> , 2015, 135, 636-642.	1.7	26
129	Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies. <i>Seminars in Perinatology</i> , 2021, 45, 151393.	2.5	26
130	The Business Case for Preconception Care: Methods and Issues. <i>Maternal and Child Health Journal</i> , 2006, 10, 93-99.	1.5	25
131	Measures of Follow-Up in Early Hearing Detection and Intervention Programs: A Need for Standardization. <i>American Journal of Audiology</i> , 2008, 17, 60-67.	1.2	25
132	Characteristics of users of intrauterine devices and other reversible contraceptive methods in the United States. <i>Fertility and Sterility</i> , 2011, 96, 1138-1144.	1.0	25
133	Prevention of Venous Thromboembolism in Pregnancy: A Review of Guidelines, 2000â€“2011. <i>Journal of Women's Health</i> , 2012, 21, 611-615.	3.3	25
134	The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. <i>Milbank Quarterly</i> , 2016, 94, 366-391.	4.4	25
135	CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 888-890.	15.1	25
136	CDC Grand Rounds: preventing hospital-associated venous thromboembolism. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 190-3.	15.1	25
137	Hospital use, associated costs, and payer status for infants born with spina bifida. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2012, 94, 1044-1053.	1.6	24
138	Health care expenditures associated with venous thromboembolism among children. <i>Thrombosis Research</i> , 2012, 129, 583-587.	1.7	24
139	Databases for Congenital Heart Defect Public Health Studies Across the Lifespan. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	24
140	Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al.. <i>Thrombosis and Haemostasis</i> , 2012, 107, 192-193.	3.4	23
141	Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?. <i>European Journal of Human Genetics</i> , 2014, 22, 25-31.	2.8	23
142	Hospitalizations and associated costs in a populationâ€“based study of children with Down Syndrome born in Florida. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 826-836.	1.6	23
143	Points to consider in assessing and appraising predictive genetic tests. <i>Journal of Community Genetics</i> , 2010, 1, 185-194.	1.2	22
144	Observed and expected frequencies of structural hemoglobin variants in newborn screening surveys in Africa and the Middle East: deviations from Hardy-Weinberg equilibrium. <i>Genetics in Medicine</i> , 2016, 18, 265-274.	2.4	22

#	ARTICLE	IF	CITATIONS
145	Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28703.	1.5	22
146	Variation in immunoreactive trypsinogen concentrations among michigan newborns and implications for cystic fibrosis newborn screening. <i>Pediatric Pulmonology</i> , 2011, 46, 125-130.	2.0	21
147	National Health Care Expenditures Associated With Disability. <i>Medical Care</i> , 2020, 58, 826-832.	2.4	21
148	Health Utility Elicitation. <i>Pharmacoeconomics</i> , 2012, 30, 83-86.	3.3	20
149	Racial/ethnic differences in hospital use and cost among a statewide population of children with Down syndrome. <i>Research in Developmental Disabilities</i> , 2013, 34, 3276-3287.	2.2	20
150	Scoping review of patient- and family-oriented outcomes and measures for chronic pediatric disease. <i>BMC Pediatrics</i> , 2015, 15, 7.	1.7	20
151	Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002â€“2008. <i>Contraception</i> , 2012, 85, 155-159.	1.5	19
152	Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. <i>Genetics in Medicine</i> , 2014, 16, 225-227.	2.4	19
153	Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2076-2081.	1.5	19
154	The economic impact of an urban asthma management program. <i>American Journal of Managed Care</i> , 2009, 15, 345-51.	1.1	19
155	The role of health technology assessment in coverage decisions on newborn screening. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 313-321.	0.5	18
156	Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 731-734.	1.3	18
157	Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review. <i>International Journal of Neonatal Screening</i> , 2017, 3, 34.	3.2	17
158	Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003â€“2015. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 2950-2958.	2.7	17
159	Sociodemographic Characteristics of Families of Children with Down Syndrome and the Economic Impacts of Child Disability on Families. <i>International Review of Research in Mental Retardation</i> , 2010, , 257-294.	0.7	16
160	A National Profile of Health Care and Family Impacts of Children With Muscular Dystrophy and Special Health Care Needs in the United States. <i>Journal of Child Neurology</i> , 2012, 27, 569-576.	1.4	16
161	Prevention of orofacial clefts caused by smoking: Implications of the Surgeon General's report. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 822-825.	1.6	16
162	Determinants of Venous Thromboembolism among Hospitalizations of US Adults: A Multilevel Analysis. <i>PLoS ONE</i> , 2015, 10, e0123842.	2.5	16

#	ARTICLE	IF	CITATIONS
163	Factors associated with the timeliness of postnatal surgical repair of spina bifida. <i>Child's Nervous System</i> , 2016, 32, 1479-1487.	1.1	16
164	Screening for Congenital Cytomegalovirus After Newborn Hearing Screening: What Comes Next?. <i>Pediatrics</i> , 2017, 139, e20163837.	2.1	16
165	The need for a next-generation public health response to rare diseases. <i>Genetics in Medicine</i> , 2017, 19, 489-490.	2.4	16
166	Adherence to Recommended Care Guidelines in the Treatment of Preschool-Age Medicaid-Enrolled Children With a Diagnosis of ADHD. <i>Psychiatric Services</i> , 2019, 70, 26-34.	2.0	16
167	Quality monitoring for early hearing detection and intervention programs to optimize performance. <i>Mental Retardation and Developmental Disabilities Research Reviews</i> , 2003, 9, 73-78.	3.6	15
168	Newborn screening for inherited metabolic disease. <i>Lancet, The</i> , 2007, 369, 5-6.	13.7	15
169	Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. <i>Haemophilia</i> , 2019, 25, 456-462.	2.1	15
170	Long-term economic effect of early childhood nutrition. <i>Lancet, The</i> , 2008, 371, 365-366.	13.7	14
171	Health care expenditures among children with and those without spina bifida enrolled in Medicaid in North Carolina. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2011, 91, 1019-1027.	1.6	14
172	What Contribution Did Economic Evidence Make to the Adoption of Universal Newborn Hearing Screening Policies in the United States?. <i>International Journal of Neonatal Screening</i> , 2018, 4, 25.	3.2	14
173	Genomic sequencing in acutely ill infants: what will it take to demonstrate clinical value?. <i>Genetics in Medicine</i> , 2019, 21, 269-271.	2.4	14
174	Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs. <i>Current Medical Research and Opinion</i> , 2021, 37, 769-779.	1.9	14
175	Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001-2008 National Hospital Discharge Survey. <i>PLoS ONE</i> , 2012, 7, e34048.	2.5	14
176	Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening. <i>Ethnicity and Health</i> , 2011, 16, 377-388.	2.5	13
177	A Public Health Framework for Rare Blood Disorders. <i>American Journal of Preventive Medicine</i> , 2011, 41, S319-S323.	3.0	13
178	Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 267-283.	1.4	13
179	Ensuring the Life-Span Benefits of Newborn Screening. <i>Pediatrics</i> , 2019, 144, e20190904.	2.1	13
180	Estimation of Coronavirus Disease 2019 Hospitalization Costs From a Large Electronic Administrative Discharge Database, March 2020-July 2021. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab561.	0.9	13

#	ARTICLE	IF	CITATIONS
181	Factors associated with high hospital resource use in a population-based study of children with orofacial clefts. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2015, 103, 127-143.	1.6	12
182	Treatment Discontinuation within 3 Years of Levothyroxine Initiation among Children Diagnosed with Congenital Hypothyroidism. <i>Journal of Pediatrics</i> , 2020, 223, 136-140.	1.8	12
183	Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010. <i>PLoS ONE</i> , 2016, 11, e0153257.	2.5	11
184	Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009-2015. <i>Clinical Therapeutics</i> , 2018, 40, 430-439.e1.	2.5	11
185	US State-Level Infertility Insurance Mandates and Health Plan Expenditures on Infertility Treatments. <i>Maternal and Child Health Journal</i> , 2019, 23, 623-632.	1.5	11
186	Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia. <i>International Journal of Neonatal Screening</i> , 2020, 6, 82.	3.2	11
187	Progress in Documented Early Identification and Intervention for Deaf and Hard of Hearing Infants: CDC's Hearing Screening and Follow-up Survey, United States, 2006-2016. <i>Journal of Early Hearing Detection and Intervention</i> , 2018, 3, 1-7.	0.2	11
188	The Continuing Health Burden of Congenital Hypothyroidism in the Era of Neonatal Screening. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1671-1673.	3.6	10
189	The Jamaican Historical Experience of the Impact of Educational Interventions on Sickle Cell Disease Child Mortality. <i>American Journal of Preventive Medicine</i> , 2012, 42, e101-e103.	3.0	10
190	Laboratory testing and diagnostic coding for cytomegalovirus among privately insured infants in the United States: a retrospective study using administrative claims data. <i>BMC Pediatrics</i> , 2013, 13, 90.	1.7	10
191	Health and economic outcomes of newborn screening for infantile-onset Pompe disease. <i>Genetics in Medicine</i> , 2021, 23, 758-766.	2.4	10
192	Spending on Young Children With Autism Spectrum Disorder in Employer-Sponsored Plans, 2011-2017. <i>Psychiatric Services</i> , 2021, 72, 16-22.	2.0	10
193	Cost or price of sequencing? Implications for economic evaluations in genomic medicine. <i>Genetics in Medicine</i> , 2021, 23, 1833-1835.	2.4	10
194	Reading Proficiency Trends Following Newborn Hearing Screening Implementation. <i>Pediatrics</i> , 2021, 148, .	2.1	10
195	Early Hearing Detection and Intervention in the United States: Achievements and Challenges in the 21st Century. <i>China CDC Weekly</i> , 2020, 2, 378-382.	2.3	10
196	The Income-Based Human Capital Valuation Methods in Public Health Economics Used by Forensic Economics. <i>Journal of Forensic Economics</i> , 2011, 22, 43-57.	0.3	10
197	Prevalence of Venous Thromboembolism Among Privately Insured US Adults. <i>Archives of Internal Medicine</i> , 2010, 170, 1774.	3.8	9
198	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 70.	2.7	9

#	ARTICLE	IF	CITATIONS
199	Outpatient medical conditions among children and adults with spina bifida in the United States: Frequency and expenditures. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2010, 3, 177-185.	0.5	8
200	Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. <i>MDM Policy and Practice</i> , 2018, 3, 238146831876381.	0.9	8
201	State-Level Health Care Expenditures Associated With Disability. <i>Public Health Reports</i> , 2021, 136, 441-450.	2.5	8
202	Monetary Valuation of Children's Cognitive Outcomes in Economic Evaluations from a Societal Perspective: A Review. <i>Children</i> , 2021, 8, 352.	1.5	8
203	Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019. <i>Journal of Pediatrics</i> , 2022, 246, 274-278.e2.	1.8	7
204	On the Alleged Antebellum Surge in Wage Differentials: A Critique of Williamson and Lindert. <i>Journal of Economic History</i> , 1982, 42, 413-418.	1.2	6
205	Cost Savings From Universal Newborn Hearing Screening. <i>Pediatrics</i> , 2006, 118, 844a-845.	2.1	6
206	Leveraging birth defects surveillance data for health services research. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014, 100, 815-821.	1.6	6
207	Understanding and Improving Health Education Among First-time Parents of Infants With Sickle Cell Anemia in Alabama. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 35-42.	0.6	6
208	Economic evaluations of newborn screening. , 2009, , 113-132.		6
209	Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection. <i>Current Medical Research and Opinion</i> , 2022, 38, 273-275.	1.9	6
210	Post-traumatic stress disorder, anxiety, and depression among adults with congenital heart defects. <i>Birth Defects Research</i> , 2022, 114, 124-135.	1.5	6
211	Laboratory testing for cytomegalovirus among pregnant women in the United States: a retrospective study using administrative claims data. <i>BMC Infectious Diseases</i> , 2012, 12, 334.	2.9	5
212	Exome sequencing: value is in the eye of the beholder. <i>Genetics in Medicine</i> , 2020, 22, 280-282.	2.4	5
213	Heterogeneity in Autism Spectrum Disorder Case-Finding Algorithms in United States Health Administrative Database Analyses. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4150-4163.	2.7	5
214	Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents With Congenital Adrenal Hyperplasia. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa152.	0.2	5
215	The Skinny on COI Analysis. <i>Obesity</i> , 2004, 12, 1189-1189.	4.0	4
216	Self-selection and evaluation of influenza vaccination effectiveness among elderly. <i>Vaccine</i> , 2006, 24, 6374-6375.	3.8	4

#	ARTICLE	IF	CITATIONS
217	Assessing the Hereditary Hemorrhagic Telangiectasia Algorithms in a Community-Based Patient Population. , 2019, 23, .		4
218	Assessing the evidence for clinical utility in newborn screening. , 2009, , 517-532.		4
219	In Reference to: "Cost and Utility of Thrombophilia Testing" Journal of Hospital Medicine, 2017, 12, 783-783.	1.4	4
220	Exploring options for expanded newborn screening. Journal of Law, Medicine and Ethics, 2005, 33, 46-8.	0.9	4
221	Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 379-382.	1.3	4
222	"Regime Type and Performance: A Blind Alley?" Comparative Political Studies, 1982, 14, 543-548.	3.6	3
223	What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to say. American Journal of Obstetrics and Gynecology, 2010, 202, 209-211.	1.3	3
224	Is universal tumor testing for Lynch syndrome cost-effective? It depends!. Genetics in Medicine, 2019, 21, 252-253.	2.4	3
225	Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies. Muscle and Nerve, 2021, 64, 717-725.	2.2	3
226	Assisting states in assessing newborn screening options. Public Health Reports, 2001, 116, 169-172.	2.5	3
227	Medicaid healthcare expenditures for infants with birth defects potentially related to Zika virus infection in North Carolina, 2011"2016. Birth Defects Research, 2022, 114, 80-89.	1.5	3
228	The politics of family planning in the Maghrib. Studies in Comparative International Development, 1982, 17, 22-48.	1.7	2
229	Outcomes in CAH: Need for Evidence-Based Estimates. Hormone Research in Paediatrics, 2007, 68, 203-203.	1.8	2
230	What we don't know can hurt us: Nonresponse bias assessment in birth defects research. Birth Defects Research Part A: Clinical and Molecular Teratology, 2015, 103, 603-609.	1.6	2
231	Medical expenditures for hypertensive disorders during pregnancy that resulted in a live birth among privately insured women. Pregnancy Hypertension, 2021, 23, 155-162.	1.4	2
232	Economic evaluation of Zika Contraception Access Network in Puerto Rico during the 2016"17 Zika virus outbreak. Contraception, 2022, 107, 68-73.	1.5	2
233	Decision Analysis, Economic Evaluation, and Newborn Screening. Obstetrical and Gynecological Survey, 2012, 67, 758-760.	0.4	1
234	Modeling uncertain outcomes of genetic testing: factor V Leiden mutation and pregnant women. Genetics in Medicine, 2013, 15, 335-337.	2.4	1

#	ARTICLE	IF	CITATIONS
235	Does Newborn Screening Have 100% Sensitivity to Detect Salt-Wasting Congenital Adrenal Hyperplasia?. JAMA Pediatrics, 2014, 168, 970.	6.2	1
236	Cost-of-illness models for venous thromboembolism: One size does not fit all. Thrombosis Research, 2016, 145, 65-66.	1.7	1
237	Association of US State Implementation of Newborn Screening Policies for Critical Congenital Heart Disease With Early Infant Cardiac Deaths. Obstetrical and Gynecological Survey, 2018, 73, 260-262.	0.4	1
238	Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework. Pediatrics, 2021, 148, s45-s50.	2.1	1
239	Return on Investment and Economic Evaluation. , 2015, , 225-232.		1
240	Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state. Muscle and Nerve, 2022, 65, 574-580.	2.2	1
241	Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines. Applied Health Economics and Health Policy, 2022, , 1.	2.1	1
242	Epidemiology matters: peering inside the "black box" in economic evaluations of genetic testing. Genetics in Medicine, 2016, 18, 963-965.	2.4	0
243	How Economic Findings Can Inform Prevention Research in Cardiovascular Disease. American Journal of Preventive Medicine, 2017, 53, S118-S120.	3.0	0
244	Avoiding Harm From Hyperbilirubinemia Screening"Reply. JAMA Pediatrics, 2019, 173, 1209.	6.2	0
245	Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Affairs, 2019, 38, 328-328.	5.2	0
246	Fragile X Syndrome-Associated Emergency Department Visits in the United States, 2006"2011. American Journal on Intellectual and Developmental Disabilities, 2020, 125, 103-108.	1.6	0
247	Genetics and prevention effectiveness. , 2000, , 329-360.		0
248	Private Insurance Reimbursements for Newborn Hearing Screening in the United States, 2013-2014 Birth Cohort. Journal of Early Hearing Detection and Intervention, 2020, 5, 13-19.	0.2	0